martes, 2 de julio de 2019

Cancer Information Highlights, July 2, 2019

Cancer Information Highlights, July 2, 2019

National Cancer Institute

Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
 
New from NCI
Video—Randomization in Clinical Trials
screen shot of video This video explains how and why researchers randomly assign clinical trial participants to different treatment groups in some clinical trials.
Targeted Therapy for Pancreatic Cancer

Results from a large clinical trial suggest that a targeted cancer drug already used to treat some women with ovarian and breast cancer may also benefit some people with advanced pancreatic cancer who have certain changes in the BRCA1 or BRCA2 gene.
More Treatment Options for Metastatic Prostate Cancer
Enzalutamide and apalutamide block the androgen receptor (AR) on cancer cells, blunting androgen's (A) ability to fuel prostate cancer growth. Read about two large clinical trials that each tested a different antiandrogen drug combined with androgen deprivation therapy in men with metastatic prostate cancer.
Advances in Breast Cancer Research

This page highlights some of the latest research in breast cancer, including research that may soon translate into improved care, NCI-supported programs that are fueling progress, and research findings from recent studies.
Advances in Colorectal Cancer Research

Learn how NCI-funded researchers are working to advance our understanding of how to prevent, detect, and treat colon and rectal cancers.
Drug Information Updates
New Approval for Breast Cancer

We've added a new drug information summary for alpelisib (Piqray), which was recently approved by the Food and Drug Administration (FDA) for use with fulvestrant to treat certain people with advanced or metastatic breast cancer that has a mutation in the PIK3CA gene.
New Approval for Diffuse Large B-Cell Lymphoma

We've added a new drug information summary for polatuzumab vedotin-piiq (Polivy), which was recently approved by FDA for use with bendamustine hydrochloride and rituximab to treat certain adults with diffuse large B-cell lymphoma that has relapsed or not gotten better.
 
Also of Interest
Managing Costs and Medical Information

When you have cancer, keeping track of tests and treatments, paperwork, bills, and other records can seem overwhelming. Learn how to manage all this paperwork and gain control.
Tumor Markers

Review the latest update of this page. Learn what tumor markers are and how they are used to help diagnose cancer and plan treatment.

No hay comentarios:

Publicar un comentario